Doctors Frustrated By Lack Of Guidance On Who Should Get Aduhelm
Broad Label Has No Requirement To Test For Amyloid
Executive Summary
Biogen has warned that uptake for its newly approved Alzheimer’s therapy will be slow in the beginning and doctors confirm it will take time to figure which patients can and should be treated.
You may also be interested in...
Aduhelm’s Revised Labeling Could Help Payers Navigate Reimbursement
The US FDA revised labeling to clarify the target population, which could be helpful in reimbursement discussions for the Alzheimer's therapy.
Quick Listen: Scrip’s Five Must-Know Things
In this week's podcast edition of Scrip's Five Must-Know Things: new developments in the TIGIT field; doctor frustration over Aduhelm guidance; are pediatric COVID vaccines necessary: the battle of the SERDs; and one Indian firm’s plans for lung disease leadership.
Biogen Gives Up On Gosuranemab After No Benefit Seen In Alzheimer's Study
Biogen’s investigational anti-tau antibody gosuranemab has missed its primary efficacy endpoint in a Phase II study in patients with Alzheimer's disease, prompting the end of the trial and termination of the compound’s further clinical development.